BCL2L1 and acute myeloid leukemia: To explore whether MNT loss could sensitize the AML cells to BH3 mimetic drugs, 5 independent Mntfl/flCreERT2/MLL::AF9 AML CLs were treated for 24 hours with 4-OHT or vehicle (ethanol) and then for another 24 hours with S63845 (MCL-1 inhibitor), ABT-199/venetoclax (BCL-2 inhibitor), A-1331852 (BCL-XL inhibitor), or vehicle (dimethyl sulfoxide) in the presence of 4-OHT.